pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL · news · pharmadog
← back to BRISTOL
News mentioning BRISTOL
354
stories
Sep 2, 26
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
Sep 1, 26
Alumis’ TYK2 drug fails in key lupus study
biopharma dive
Sep 1, 26
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
Sep 1, 26
ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T
biospace
Sep 1, 26
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Sep 1, 26
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
fiercebiotech
Sep 1, 26
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
endpoints
Aug 31, 26
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
biopharma dive
Aug 31, 26
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
fiercebiotech
Aug 31, 26
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
biopharma dive
Aug 31, 26
Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
biospace
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 31, 26
China poses increasing security risk as US biotech innovation edge erodes
biospace
Aug 27, 26
Opinion: STAT+: A bill is supposed to protect U.S. biotech from Chinese competition. But there’s a loophole
stat
Aug 26, 26
Cellares rebukes Bristol Myers' criticism of its cell therapy technology
endpoints
Aug 26, 26
BMS ends Cellares pact over cell therapy production problems, triggering layoffs
biospace
Aug 25, 26
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg
endpoints
Aug 24, 26
Cellares, a cell therapy manufacturing specialist, to lay off 100 employees
biopharma dive
Aug 24, 26
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
biospace
Aug 23, 26
Why a Texas congressman believes Chinese biotechs are 'beating us on our ground game'
fiercebiotech
Aug 21, 26
Shareholder pressures Capricor; Lilly dives deeper into vaccines
biopharma dive
Aug 20, 26
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
Aug 20, 26
STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
stat
Aug 20, 26
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
Aug 19, 26
STAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and more
stat
Aug 19, 26
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
Aug 19, 26
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
Aug 18, 26
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
Aug 18, 26
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
← prev
page 6 of 12
next →
